<DOC>
	<DOCNO>NCT00051116</DOCNO>
	<brief_summary>To evaluate response rate , response duration , survival patient treat CC-5013 chronic dosing schedule versus syncopate dose schedule .</brief_summary>
	<brief_title>A Phase II Study Continuous Versus Syncopated Dosing CC-5013 Treatment Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>History histologically document multiple myeloma relapse resistant disease Pregnant nursing woman may participate . Women childbearing potential must negative pregnancy document within one week registration . Women reproductive potential may participate unless agree use effective contraceptive method . Signed write informed consent willingness meet followup schedule study procedure obligation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
	<keyword>CC-5013</keyword>
</DOC>